In vivo use of the CYP inhibitor 1‐aminobenzotriazole to increase long‐term exposure in mice
- 5 July 2016
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 37 (6) , 373-378
Abstract
1-Aminobenzotriazole (ABT) is a well-known in vivo nonspecific inhibitor of cytochrome P450 (CYP) enzymes. An effective dosing regimen of ABT for a multiple-administration study is needed to conduct pharmacological studies for proof-of-concept, although it has been established for single-administration study, to characterize the pharmacokinetics of drug candidates. This study demonstrated a suitable dosing vehicle of ABT for continuous administration and increased exposure to antipyrine, which is a nonspecific probe of CYP, using ABT for a long period in mice. The dosing vehicle of ABT was 0.5% (w/v) hydroxypropyl methylcellulose and 0.5% (v/v) Tween 80 in N,N-dimethylacetamide/20% hydroxypropyl-β-cyclodextrin aqueous solution (2:8, v/v) based on the duration of apparent solubility. After implantation of an ALZET osmotic pump with ABT, the plasma concentrations of ABT were maintained at more than 4.1 μg/ml over 336 h. Compared with the vehicle group, the CLtot of antipyrine with ABT decreased to approximately one-fourth, and the BA of antipyrine with ABT increased up to 3-fold. In addition, the enhancement of exposure of antipyrine by ABT was maintained over the 336 h. The body weight, food consumption and hematological parameters of mice did not change with ABT administration for 16 days. These findings demonstrated that pretreatment of ABT can increase long-term exposure using continuous administration with the ALZET osmotic pump in mice with no overt toxicity. It is concluded that the in vivo use of 1-aminobenzotriazole can be applied to pharmacological studies for proof-of-concept, thus contributing to the selection of drug candidates at an early drug discovery stage. Copyright © 2016 John Wiley & Sons, Ltd.Keywords
This publication has 20 references indexed in Scilit:
- Using Improved Serial Blood Sampling Method of Mice to Study Pharmacokinetics and Drug–Drug InteractionJournal of Pharmaceutical Sciences, 2015
- 1-Aminobenzotriazole Modulates Oral Drug Pharmacokinetics through Cytochrome P450 Inhibition and Delay of Gastric Emptying in RatsDrug Metabolism and Disposition, 2014
- Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limitsXenobiotica, 2013
- A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next?Expert Opinion on Drug Metabolism & Toxicology, 2013
- 1-Aminobenzotriazole, a Known Cytochrome P450 Inhibitor, Is a Substrate and Inhibitor of N-AcetyltransferaseDrug Metabolism and Disposition, 2011
- Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with anN-sulfonylated dipeptide VLA-4 antagonist in ratsXenobiotica, 2008
- EFFECTIVE DOSING REGIMEN OF 1-AMINOBENZOTRIAZOLE FOR INHIBITION OF ANTIPYRINE CLEARANCE IN GUINEA PIGS AND MICE USING SERIAL SAMPLINGDrug Metabolism and Disposition, 2004
- Distribution of 1-aminobenzotriazole in male rats after administration of an oral doseXenobiotica, 1993
- Metabolism of metronidazole and antipyrine in hepatocytes isolated from mouse and ratXenobiotica, 1990
- In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT)Biochemical Pharmacology, 1988